BioCanRx – Cancer Stakeholder Alliance Joint Action Plan

The plan of action of the Cancer Stakeholder Alliance Working Group

 

Overview

 

Based on the shared priorities of BioCanRx and the Cancer Stakeholder Alliance, the Joint Action Plan outlines the objectives and activities for the BioCanRx Cancer Stakeholder Alliance Working Group. The overall goals of the Joint Action Plan are to help ensure

 

  • the inclusion of the experience and perspective of cancer patients, their families and the concerned public in BioCanRx activities and projects; and
  • the accessibility of BioCanRx research information.

 

Over the course of its first funding cycle, BioCanRx is partnering with the Cancer Stakeholder Alliance Working Group to execute the Joint Action Plan.

 

The priorities of Joint Action Plan are identified by the Cancer Stakeholder Alliance on an annual basis, and are also based on the Terms of Reference of the Cancer Stakeholder Alliance and Cancer Stakeholder Alliance Working Group.

 

Joint Action Plans

 

See the links below for additional information on current and past BioCanRx-Cancer Stakeholder Alliance Joint Action plans:

 

 

Contact

 

For more information about the BioCanRx-Cancer Stakeholder Alliance Joint Action Plan, please contact Renée Leduc, Manager of Knowledge Mobilization at BioCanRx, by email (rleduc@biocanrx.com).

 

2017 Joint Action Plan

 

The BioCanRx-Cancer Stakeholder Alliance Joint Action Plan of the 2017 Cancer Stakeholder Alliance Working Group was launched in January 2017 and includes three priorities identified by the Cancer Stakeholder Alliance in October 2016:

 

  • Patient Clinical Trials Information
  • The Learning Institute
  • Patient Perspective in Research

 

Stay tuned for the “Report of the 2017 Cancer Stakeholder Alliance Working Group on the BioCanRx-Cancer Stakeholder Alliance Joint Action Plan”, which is anticipated for January 2018.

 

Priority: Patient Clinical Trials Information

 

Action: Create a new standard of communicating BioCanRx clinical trial information to patients

 

Description: BioCanRx and the Cancer Stakeholder Alliance Working Group are working together to develop and validate BioCanRx lay research information that will be available to the public on the BioCanRx website. This action is being executed during the 2017 calendar year.

 

2017 Cancer Stakeholder Alliance Working Group Co-leads:

 

Kathy Brodeur-Robb, Executive Director, C17 (Children’s Cancer and Blood Disorders) Nancy Boyle, Director, Communications, Marketing & Engagement, BioCanRx Renée Leduc, Manager, Knowledge Mobilization, BioCanRx Tammy Northam, Executive Director, Bladder Cancer Canada

 

With help from

 

Danielle Jones, Officer, Communications & Marketing, BioCanRx Kelley Parato, Director, Scientific Affairs, BioCanRx

 

Priority: The Learning Institute

 

Action: Forge connections between the BioCanRx research community and cancer patients, charities and NGOs by creating a knowledge exchange event at the Summit for Cancer Immunotherapy that enables dialogue and understanding of science and patient needs.

 

Description: BioCanRx and the Cancer Stakeholder Alliance Working Group are co-developing a Learning Institute for patient leaders and academic scholars at the annual BioCanRx Summit for Cancer Immunotherapy. This action is being executed during the 2017 calendar year and includes piloting the first Learning Institute at the June 2017 Summit for Cancer Immunotherapy.

 

2017 Cancer Stakeholder Alliance Working Group Co-leads:

 

Louise Binder, Health Policy Consultant, Save Your Skin Foundation Kathy Brodeur-Robb, Executive Director, C17 (Children’s Cancer and Blood Disorders) Linda Eagen, President & CEO, Ottawa Regional Cancer Foundation
Renée Leduc, Manager, Knowledge Mobilization, BioCanRx Patrick Sullivan, President, Team Finn Foundation; A Founder and Chairman, Ac2orn Jovian Tsang, Manager, HQP Training Programs

 

With help from

 

Nicole Forbes, Research Associate Research Associate, Ottawa Hospital Research Institute Brittany Umer, PhD Candidate, University of Alberta

 

For more information about the BioCanRx-Cancer Stakeholder Alliance Learning Institute, click here.

 

Priority: Patient Perspective in Research

 

Action: Integrate the cancer patient perspective in BioCanRx research

 

Description: BioCanRx and the Cancer Stakeholder Alliance Working Group are co-organizing a panel at the June 2017 Summit for Cancer Immunotherapy featuring critical guidance and expertise to the BioCanRx Network on best practices in developing the right patient partnerships for co-developing research strategies and programs. This panel, and ongoing engagement with the Cancer Stakeholder Alliance and the Ottawa SPOR Support Unit, will define a path for patient engagement in the BioCanRx research program writ large. It will ensure that the BioCanRx research projects and overall program remain relevant from the cancer patient stakeholder perspective. This action is being executed over the course of the first funding cycle of the Network.

 

2017 Cancer Stakeholder Alliance Working Group Co-leads:

 

John-Peter Bradford, CEO, Life Saving Therapies Network Renée Leduc, Manager, Knowledge Mobilization, BioCanRx Kelley Parato, Director, Scientific Affairs, BioCanRx Patrick Sullivan, President, Team Finn Foundation; A Founder and Chairman, Ac2orn